Omacetaxine is a first-in-class cetaxine with clinical activity against Philadelphia-positive (Ph+) chromosome chronic myeloid leukemia (CML) and a mechanism of action independent of tyrosine kinase inhibition. Currently available tyrosine kinase inhibitors have not demonstrated activity in CML patients who harbor the Bcr-Abl T315I mutation. A new study shows that subcutaneous-administered omacetaxine is safe and effective in imatinib-resistant CML patients who harbor the Bcr- Abl T315I Mutation.